Zobrazeno 1 - 5
of 5
pro vyhledávání: '"63"'
Autor:
Huseyin Tepetam, Sevgi Ozden, Hazan Ozyurt, Cengiz Gemici, Ozlem Yetmen, Alpaslan Mayadagli, Gokhan Yaprak
Publikováno v:
BMC Cancer
Background: Anemia is a major cause of morbidity in patients with cancer resulting in poor physical performance, prognosis and therapy outcome. The aim of this study is to assess the efficacy of intravenous (iv) iron administration for the correction
Autor:
Awais Javed, Raymond U. Osarogiagbon, Upender Manne, Ruixiao Lu, Rangaswamy Govindarajan, Fade Mahmoud, James Posey, Ahmed Y. Javed, Trafina Jadhav, Calvin Y. Chao
Publikováno v:
BMC Cancer
Background African American (AA) colon cancer patients have a worse prognosis than Caucasian (CA) colon cancer patients, however, reasons for this disparity are not well understood. To determine if tumor biology might contribute to differential progn
Publikováno v:
BMC Cancer, Vol 2, Iss 1, p 19 (2002)
BMC Cancer
BMC Cancer
Background In recent years it has become evident that nonsteroidal anti-inflammatory drugs, in particular aspirin represent a potential class of cancer chemotherapeutic agents. Despite the wealth of knowledge gained from epidemiological, clinical and
Autor:
Florence Richard, Yves-Marie Robin, Philippe Martin, Carlos Maynou, Karine Ligier, Xavier Leroy, Stéphanie Clisant, Nicolas Penel
Publikováno v:
BMC Cancer
Background Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study. To improve the initial management of adult sarcomas, a regional exper
Autor:
Gabriela Altorjai, Rupert Bartsch, W. Koestler, Christoph C. Zielinski, Ursula Sevelda, Gottfried J. Locker, Ursula Pluschnig, Robert M. Mader, Catharina Wenzel, Dagmar Hussian, Guenther G. Steger
Publikováno v:
BMC Cancer, Vol 6, Iss 1, p 63 (2006)
BMC Cancer
BMC Cancer
Background Combining trastuzumab and chemotherapy is standard in her2/neu overexpressing advanced breast cancer. It is not established however, whether trastuzumab treatment should continue after the failure of one earlier combination. In this trial,